The Effect of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve Parameters and Intra-cytoplasmic Sperm Injection Outcomes in Patient With Poor Ovarian Reserve: an Open Label Randomized Clinical Trial

To evaluate the role of Myo-inositol, melatonin and co-enzyme Q10 on ovarian reserve parameters and ICSI outcome in poor ovarian responder

Start Date30 Jun 2024

Sponsor / Collaborator

Beni-Suef University

NCT06405243 / Not yet recruitingPhase 3IIT

The Combination of Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

The aim of the study is to compare and assess the efficacy of combined letrozole with myoinositol, chromium, or L-arginine in infertile women with PCOS. This study will help in the investigation of alternative therapeutic modalities for fertility improvement in polycystic ovarian syndrome

Start Date30 Jun 2024

Sponsor / Collaborator

Beni-Suef University

IRCT20220417054557N2 / RecruitingPhase 3IIT

Investigation the effect of Inositol in patients with Primary Sclerosing Cholangitis

Start Date10 Mar 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

100 Clinical Results associated with Inositol

100 Translational Medicine associated with Inositol

100 Patents (Medical) associated with Inositol

1,708

Literatures (Medical) associated with Inositol

31 Dec 2024·Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome

Review

Author: Lete, Iñaki ; Martínez, Ainara ; Lasaga, Irene ; Centurión, Eva ; Vesga, Amaia

In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS. The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.

01 May 2024·Food chemistry

Enhancing physicochemical and functional properties of myo-inositol in crystallization with edible sugar additives

Article

Author: Li, Kangli ; Zhang, Leida ; Wei, Xuemei ; Gong, Junbo ; Wang, Xiaowei ; Shen, Runpu ; Zhao, Wei ; Chen, Mingyang ; Han, Dandan

Myo-inositol, referred to as vitamin B8, is an essential nutrient for maintaining human physiological functions. However, the morphology of myo-inositol products is predominantly powder or needle shaped, leading to poor food properties. In this work, three edible sugar additives, i.e. d-glucose, l-arabinose and d-fructose, are adopted in the crystallization of myo-inositol to improve its food properties. The results show that these additives change the morphology of myo-inositol crystals. d-glucose and l-arabinose reduced the aspect ratio of myo-inositol crystals, and d-glucose transformed elongated lamellar myo-inositol crystals into diamond-shaped lamellar crystals. The diamond-shaped lamellar myo-inositol products exhibited outstanding functional food properties. It offered a smoother texture and more pleasant mouthfeel when the products were added to infant formulas and nutraceuticals. When they were applied to functional beverages, the dissolution rate was increased by 35 %. This work provides a theoretical guidance for improving food properties through crystallization and possesses considerable potential for industrialization.

01 Mar 2024·Cryobiology

Effect of type and concentration of antioxidant on sperm motility, viability, and DNA integrity of climbing perch Anabas testudineus Bloch, 1792 (Pisces: Anabantidae) post-cryopreservation

Article

Author: Fadli, Nur ; Rahayu, Sri R ; Kocabas, Filiz K ; Maulida, Siti ; Kocabas, Mehmet ; Wilkes, Martin ; Siti-Azizah, Mohd N ; Muchlisin, Zainal A ; Handayani, Luvi S ; Eriani, Kartini

Sperm quality is preserved through the crucial involvement of antioxidants, which play a vital role in minimizing the occurrence of reactive oxygen species (ROS) during the cryopreservation process. The suitability of the type and concentration of antioxidants are species-dependent, and this study is crucial in order to improve the quality of the climbing perch sperm post-cryopreservation. Therefore, this study aimed to determine the best type and concentration of antioxidants for cryopreservation of climbing perch Anabas testudineus sperm. To achieve this, 6 types of antioxidants, namely, ascorbic acid, beta-carotene, glutathione, butylated hydroxytoluene (BHT), myo-inositol, and alpha-tocopherol, with inclusion of a control were tested in 3 replications at three concentration levels of 0 mg/L (control), 20 mg/L, 40 mg/L, and 60 mg/L. Sperm was diluted in a glucose-base extender at a ratio of 1:60 (sperm: glucose base), then 10 % DMSO and 5 % egg yolk was added before cryopreservation for two weeks. The results showed that the type and concentration of antioxidants had a significant effect on the motility and viability of cryopreserved climbing perch sperm (P < 0.05), where the best results for ascorbic acid, beta-carotene, glutathione, myo-inositol, and alpha-tocopherol were obtained at a concentration of 60 mg/L, while BHT was at a concentration of 20 mg/L. The best results for glutathione, myo-inositol, and alpha-tocopherol were significantly different from other treatments, while the best results for ascorbic acid and beta-carotene (60 mg/L) were not significantly different from the 40 mg/L concentration, while the best results for BHT were not significantly different from the control treatments. Therefore, the best concentration of glutathione, myo-inositol, and alpha-tocopherol was 60 mg/L, while for ascorbic acid and beta-carotene it was 40 mg/L, and BHT was not recommended. DNA integrity analysis indicated the absence of fragmentation in all samples, including fresh, control, and treated sperm. Based on practical and economic considerations, myo-inositol at 60 mg/L was recommended for cryopreservation of climbing perch A. testudineus sperm.

News (Medical) associated with Inositol

22 Aug 2023

·www.globenewswire.com

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System AtrophyMELBOURNE, Australia and SAN FRANCISCO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that poster presentations from its bioMUSE natural history study of Multiple System Atrophy (MSA) will be delivered at the International Congress of Parkinson’s Disease and Movement Disorders taking place August 27 - 31, 2023 in Copenhagen, Denmark. Title:A multimodal approach for diagnosis of early Multiple System AtrophyPresenter:Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical CenterAbstract #:162Category:Parkinsonism, Atypical: MSADate: Monday, August 28, 2023Time: 13:00 - 15:00 local time Title:Preliminary evidence for evolution of myoinositol and N-acetylaspartate as biomarkers of disease severity in early-stage Multiple System AtrophyPresenter:Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical CenterAbstract #:181Category:Parkinsonism, Atypical: MSADate:Monday, August 28, 2023Time:13:00 - 15:00 local time About bioMUSE Biomarkers of progression in Multiple System Atrophy (bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity’s randomized ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently enrolling in the Phase 2 clinical trial. About Multiple System Atrophy Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects approximately 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.1 1Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov) About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064 U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Phase 2Clinical Result

02 Aug 2023

·www.prnewswire.com

LEADING WOMEN'S HEALTH BRAND O POSITIV LAUNCHES OVARIAN SUPPORT VITAMIN CAPSULES

Supplements Support Ovarian and Reproductive Health and Aid in Regulating Menstrual Cycles LOS ANGELES, Aug. 2, 2023 /PRNewswire/ -- Today, O Positiv, the women's health brand behind FLO, the first-ever PMS support supplement on the market, introduces their newest product FLO Ovarian Support Vitamin Capsules. Continue Reading FLO Ovarian Support O Positiv's mission is to prioritize and advocate for women with effective products to address health concerns that have been historically overlooked. Since launching the FLO PMS Gummy in December 2018, O Positiv has positioned themselves as a premiere wellness brand with a range of products to address vaginal, digestive, skin, menstrual and menopausal health. Now, the brand is expanding from wellness supplements to a broader all-encompassing women's health company. O Positiv's co-founder, Brianna Bitton, was recently diagnosed with PCOS. Her struggle with painful and irregular periods continues to be a catalyst for the brand to launch much needed and effective products for women. More than 5 million women in the United States need help with Ovarian issues, especially women of reproductive age. For women suffering from hormonal imbalances, irregular periods and excess androgen levels, FLO Ovarian Support is designed to help using plant- based ingredients backed by science. "We made this product for the millions of women who know they need support for ovarian function," says co-founder Bobby Bitton, "And, so that millions more can begin the conversation with their doctors about the symptoms they're facing and how better ovarian support can help." Each FLO Ovarian Support Vitamin Capsule is formulated with the scientifically backed 40:1 ratio of Myo-Inositol and D-Chiro-Inositol to help support ovarian health and cycle regularity, folate to support reproductive health, and diindolylmethane (commonly known as DIM) to support healthy hormone levels. "Outside of cyclical PMS symptoms, hormone imbalances can cause irregular cycles and overactive hair growth. FLO Ovarian Support's ingredients help support healthy hormone levels," says Dr. Jessica Shepherd, OBGYN. "FLO Ovarian Support is great for patients who struggle with irregular cycles or overactive oil production on their face or scalp." O Positiv plans to continue expanding their range of products, which currently includes favorites - FLO PMS Gummies & Capsules, GOGO Prebiotic Fiber Gummies, URO Urinary Tract & URO Vaginal Probiotic Capsules, GOGO Bloating and Gas Capsules, MENO Menopause Gummies & Capsules and RETRO Glowing Skin Gummies & Capsules, among others. To further advocate for women's health, O Positiv works with the global nonprofit Period to end period poverty and stigma through service, education and advocacy. FLO Ovarian Support Vitamin Capsules retail $42.99 for a one-time purchase or subscription for $34.99 opositiv.com. About O Positiv O Positiv is the health and wellness brand prioritizing women by creating effective products to address health concerns that have been historically overlooked. O Positiv aims to break taboos with a line of products to address vaginal, skin, digestive, menstrual and menopausal health. For more information, visit opositiv.com. Follow O Positiv on Instagram at @opositiv Press Contact: Shauna Aminzadeh/Break Point [email protected] SOURCE O Positiv

01 Aug 2023

·www.drugs.com

Key Ingredient in Breast Milk Could Do Wonders for Baby's Brain

TUESDAY, Aug. 1, 2023 -- A micronutrient in human breast milk may provide significant benefit to developing newborn brains, according to new research that sheds light on the link between nutrition and brain health. Scientists looked at this sugar molecule in rodents and in human neurons. They said the micronutrient, called myo-inositol, may lead to improved infant formulas. “The current research does indicate that for circumstances where breastfeeding is not possible, it may be beneficial to increase the levels of myo-inositol in infant formula,” said study co-author Thomas Biederer . Myo-inositol may also play a part in the aging brain, according to the research conducted at the Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University in Boston. “Forming and refining brain connectivity from birth is guided by genetic and environmental forces as well as by human experiences,” Biederer, a senior scientist on the neuroscience and aging team at the HNRCA, said in a Tufts news release. He is also a faculty member at the Yale School of Medicine. “As a neuroscientist, it’s intriguing to me how profound the effects of micronutrients are on the brain,” Biederer said. “It’s also amazing how complex and rich human breast milk is, and I now think it is conceivable that its composition is dynamically changing to support different stages of infant brain development.” The researchers compared human milk samples collected from new mothers in Mexico City, Shanghai and Cincinnati. They found that myo-inositol is most prominent in human breast milk during the first months of lactation. This is also a time when neuronal connections known as synapses are forming rapidly in the infant brain. Myo-inositol increased both the size and number of synaptic connections between neurons in the developing brain in both rodents and humans, the researchers said. That there were similar levels of myo-inositol across women in very different geographic locations points to its generally important role in human brain development, Biederer said. In early infancy, the brain may be particularly sensitive to diet because the blood-brain barrier is more permeable, the team suggested. Among the research questions still to be answered are what the right level of myo-inositol is for optimal brain health at various stages. “My colleagues at the HNRCA and I are now pursuing research to test how micronutrients like myo-inositol may impact cells and connectivity in the aging brain,” Biederer said. “We hope this work leads to a better understanding of how dietary factors interplay with age-related brain aberrations." The findings were published recently in the Proceedings of the National Academy of Sciences . Sources Tufts University, news release, July 27, 2023 Posted August 2023

100 Deals associated with Inositol

External Link

KEGG	Wiki	ATC	Drug Bank
D08079	Inositol	A11HA07	DB13178

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arteriosclerosis	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Fatty Liver	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Hepatitis	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Hyperlipidemias	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Liver Cirrhosis	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NiPPeR Randomized Trial (Pubmed)	Not Applicable	-	1,729	myo-inositol, probiotics and micronutrient supplement (Standard supplement (control))	tzhedstfny(zkiougymdk) = onvhhpwxtc qoepqozurs (ihcjvtxann, 76.0, 105.1)	-	06 Feb 2023
				Intervention supplement (myo-inositol, probiotics, and micronutrients)	tzhedstfny(zkiougymdk) = zvdnejujzv qoepqozurs (ihcjvtxann, 80.7, 103.5)
NCT02397291 (CTgov)	Not Applicable	Pregnancy \| Fetal Growth Retardation	24	Placebo (Part 1: Measurements of Maternal and Fetal Concentrations)	lxwbmxluor(vyhnlqxgra) = iyfsqfmusa psbhriqtoq (segpyprjcu, zjzhblsnxo - iornkuemqg) View more	-	11 Nov 2021
				Myoinositol+Mannose (Part 2: Stable Isotope Studies)	lxwbmxluor(vyhnlqxgra) = hdzobjuaas psbhriqtoq (segpyprjcu, zltnaxrajy - hlhinzqgdg) View more
NCT01030575 (CTgov)	Phase 2	Obstetric Labor, Premature \| Retinopathy of Prematurity \| Bronchopulmonary Dysplasia	125	Inositol lower volume (Inositol Low Volume)	leruqbxywj(qdbmcuykwg) = zhnhgruqkt bhejkqqjkf (alyhdsatnh, nalpenqdoc - pwfhnbsdid) View more	-	12 Mar 2021
				Inositol mid-level volume (Inositol Mid-level Volume)	leruqbxywj(qdbmcuykwg) = hlfkjijmfx bhejkqqjkf (alyhdsatnh, zmmcjdrqis - kdodatoaii) View more
NCT01396486 (CTgov)	Phase 4	Mania \| Bipolar Disorder	69	Omega-3 (Omega-3/Placebo)	butduaefpm(euhgvygzrx) = ilspsgeehk srdogazlkn (lrxijcyhkl, zjalkfkqbq - egcpgqkouh) View more	-	21 Apr 2020
				Inositol (Placebo/Inositol)	butduaefpm(euhgvygzrx) = kbthgibhlb srdogazlkn (lrxijcyhkl, kmaedhrtjp - pipxyckwsl) View more
NCT01954082 (CTgov)	Phase 3	Retinopathy of Prematurity	638	myo-Inositol 5% Injection (Myo-Inositol 5% Injection)	lnfaqbuuha(ihwvnioioy) = nhorhizytr wvpolvlmqi (rzsqzdegkq, kqvidvkwrb - hoxddyegyq) View more	-	26 Sep 2018
				Placebo (5% Glucose(Dextrose))	lnfaqbuuha(ihwvnioioy) = iwysfcjxvg wvpolvlmqi (rzsqzdegkq, jqvbkshaue - zkxmumjjbm) View more
Pubmed \| Diabetes Care	Not Applicable	Diabetes, Gestational	-	Intervention group (1,100 mg myo-inositol, 27.6 mg D-chiro-inositol, and 400 μg folic acid)	ulrgsqvajq(ajmwggrgmf) = plawwhzqiv uwtiaphygd (lqiyuseewl ) View more	-	01 Jun 2017
				Control group (400 μg folic acid only)	ulrgsqvajq(ajmwggrgmf) = cltfshldth uwtiaphygd (lqiyuseewl ) View more
NCT01875445 (CTgov)	Phase 2	Trichotillomania	38	Placebo (Placebo)	vgejrzkvsb(njnuzqlbas) = wymwvdrfwu lufusumkea (puumkaxnsx, cqnztwzusd - mknwdayknc) View more	-	19 May 2017
				Inositol (Inositol)	vgejrzkvsb(njnuzqlbas) = dlpxqqhxbj lufusumkea (puumkaxnsx, lvdnypeuhi - vnehknidgv) View more
NCT01111292 (CTgov)	Phase 1/2	Recurrent Colon Cancer \| Rectal Cancer \| Dysplasia ... View more	5	Inositol (Arm I (Inositol))	mbboilkfci(pairsigmrm) = yoextsncvh lroczedciy (dpvyhlslla, hhxzqxdyiq - mwknohpvbz) View more	-	12 Jul 2016
				Placebo (Arm II (Placebo))	mbboilkfci(pairsigmrm) = ptjghmrndw lroczedciy (dpvyhlslla, vphzxsogjq - dgwmchvblo) View more
NCT00783705 (CTgov)	Phase 2	Non-Small Cell Lung Cancer \| Bronchial Diseases	85	inositol (Arm A (Myo-inositol))	dmikhipbpk(bnekneivyl) = kmiwzhfcsv nbqyfgdryt (unuwxfijso, wqcmcmmrak - hnbvgzxfwf) View more	-	25 Aug 2015
				Placebo (Arm B (Placebo))	dmikhipbpk(bnekneivyl) = rddrlhfqze nbqyfgdryt (unuwxfijso, rsxizbnajz - vwvmhrpipn) View more
NCT00012558 (STEP-BD, Pubmed \| Am J Psychiatry)	Not Applicable	Depressive Disorder, Treatment-Resistant	66	Lamotrigine	naolnstbpn(kilujfranr) = yvuqitzoji hrdysbahkk (ymbybhqnrc )	Positive	01 Feb 2006
				Inositol	naolnstbpn(kilujfranr) = skwhwismcg hrdysbahkk (ymbybhqnrc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis